MDM2 and non-small cell lung carcinoma: Additionally, mutations in EGFR, STK11, and B2M, or MDM2 amplification, are related to IO resistance or hyperprogressive disease [3–5], while TP53, KRAS, and POLE mutations are positively associated with a good response in advanced non-small cell lung cancer (NSCLC) [6–9].